HTB

PK Workshop 10th 2009

10th International Workshop on Clinical Pharmacology of HIV Therapy, 15-17 April 2009, Amsterdam

Monotherapy study may explain previous poor clinical results when abacavir and tenofovir are used in combination

Interactions between ARVs and antimalarials atovaquone and proguanil

Four weeks lopinavir/r to cover functional monotherapy when stopping HAART

Efavirenz-related studies: genetics, smoking and TDM

Atazanavir: a suitable case for TDM?

Raltegravir PK in blood plasma and the genital tract

A CYP2B6 haplotype influences nevirapine plasma concentrations following a single dose to reduce mother to child transmission

Population pharmacokinetic model of nevirapine maternal to infant transfer through breastfeeding

Phenotypic and genotypic inhibitory quotients and virologic response in treatment experienced children

Tenofovir pharmacokinetics in three tenofovir-containing regimens in children and adolescents

Bioavailability of Thai generic lopinavir/ritonavir

10th International Workshop on Clinical Pharmacology of HIV Therapy, 15-17 April 2009, Amsterdam

Efavirenz lowers levels of darunavir given as 900/100mg once daily with ritonavir

How much (or how little) ritonavir do you need to boost another PI?

Genetic markers linked to early discontinuation of three antiretrovirals